Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Director · Chief Executive Officer | March 04, 2026 | March 06, 2026 |
| Viracta Therapeutics, Inc.VIRX · Entity 85616 | Director | June 20, 2024 | June 24, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUTRO BIOPHARMA, INC.
Report date March 04, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,285 |
Ending reported balance
After 2026-03-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-04 · Exercise / conversion · Acquired 788 · Balance 21,567 Row 2 · 2026-03-04 · Tax withholding · Disposed 282 · Balance 21,285 F1: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. |
| Restricted Stock Units (RSUs)SEC Table II · derivative / convertible security · Expires 2026-03-04 | Direct | 0 |
Reported balance
After 2026-03-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-04 · Exercise / conversion · Disposed 788 · Balance 0 F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 4, 2023, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F3: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 4, 2023, subject to continued service through each vesting date.
Viracta Therapeutics, Inc.
Report date June 20, 2024 · Filed June 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2034-06-20 | Direct | 50,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 50,000 · Balance 50,000 F1: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2023 Filed Jun 9, 2023 18:19 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001209191-23-036008 · doc4.xml · derivative · entry 1 Chung Jane · CIK 0001872398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:26 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016742 · doc4.xml · derivative · entry 5 Chung Jane · CIK 0001872398 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,625 Underlying: Common Stock · 7,875 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:26 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016742 · doc4.xml · derivative · entry 4 Chung Jane · CIK 0001872398 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2027-03-01 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:26 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.79 | $0.00 |
DisclosureSEC source: 0001209191-23-016742 · doc4.xml · derivative · entry 3 Chung Jane · CIK 0001872398 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-02-28 F3 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on April 1, 2023, with 100% of the total shares vested and exercisable on March 1, 2027, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:26 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,211 | $5.79 | $18,591.69 |
DisclosureSEC source: 0001209191-23-016742 · doc4.xml · nonDerivative · entry 2 Chung Jane · CIK 0001872398 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,431 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:26 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 7,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016742 · doc4.xml · nonDerivative · entry 1 Chung Jane · CIK 0001872398 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 18:58 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $3.69 | $0.00 |
DisclosureSEC source: 0001209191-22-045492 · doc4.xml · derivative · entry 1 Chung Jane · CIK 0001872398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-08-10 F1 · derivative.exercise_date: One thirty-sixth (1/36) of the shares subject to the option shall vest monthly beginning on the one month anniversary of August 10, 2022 (the "Vesting Commencement Date"), subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 18:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-045297 · doc4.xml · derivative · entry 3 Chung Jane · CIK 0001872398 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 18,750 shares Expires 2025-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on August 9, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 18:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 6,483 | $6.60 | $42,787.80 |
DisclosureSEC source: 0001209191-22-045297 · doc4.xml · nonDerivative · entry 2 Chung Jane · CIK 0001872398 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,767 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 18:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-045297 · doc4.xml · nonDerivative · entry 1 Chung Jane · CIK 0001872398 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,500 shares acquired under the issuer's employee stock purchase plan on March 15, 2022. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 19:33 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 31,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016865 · doc4.xml · derivative · entry 2 Chung Jane · CIK 0001872398 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2026-03-04 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 19:33 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001209191-22-016865 · doc4.xml · derivative · entry 1 Chung Jane · CIK 0001872398 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2032-03-03 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on April 4, 2022, with 100% of the total shares vested and exercisable on March 4, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 17:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-050956 · doc4.xml · derivative · entry 2 Chung Jane · CIK 0001872398 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2025-08-09 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on August 9, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 17:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $18.37 | $0.00 |
DisclosureSEC source: 0001209191-21-050956 · doc4.xml · derivative · entry 1 Chung Jane · CIK 0001872398 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2031-08-08 F1 · derivative.exercise_date: The option vests as to 1/4th of the total shares on August 9, 2022 and then 1/48th of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on August 9, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.